Skip to content

Diabetic Retinopathy Care to All by 2030 – Global Webinar

FOD 2021 Global webinar

Diabetic Retinopathy Care to All by 2030 

Date: Thursday, 18th November  

Time: 0700 – 0830 hrs GMT

Looking to 2030, this webinar will explore the priorities, innovations, emerging technologies and current challenges in DR care. The session will offer insights on improving integrated people-centered diabetes care and its integration into health systems, which could catalyze and amplify efforts to provide access to care for all those who need it by 2030.

Aim: The aim of the webinar is to look at possible innovations in diabetic retinopathy (DR) care and discuss the immediate priorities to facilitate access to people-centered DR services.

Format: A moderator-led panel discussion followed by an Q&A with the audience

Talking Points:

  • What are new innovations in DR treatment?
  • What is being done to improve people-centered care and quality outcomes?
  • What are the promising changes within the early detection and coverage space?
  • How can health systems adapt to emerging technology and evolve to an efficient task sharing mode?
  • What has changed with the pandemic?

Watch the video recording by clicking on the image above (UK registrants will not be able to attend the webinar).


Dr Fabrizio D'Esposito

Dr Fabrizio D’Esposito

Dr Fabrizio D’Esposito is an Eye and Ear Health Consultant with the Regional Office for the Western Pacific of the World Health Organization. Fabrizio has more than ten years of experience in the noncommunicable diseases and eye health sectors; he has been involved in the development, implementation, and evaluation of more than 50 health programs in low- and middle-income countries. An epidemiologist and implementation research scientist, Fabrizio has a particular interest in diabetes and diabetic eye disease.


Prof. Paolo Lanzetta

Prof. Paolo Lanzetta

Paolo Lanzetta is professor and chairman of ophthalmology at the University of Udine, Italy where he is also the director of the ophthalmology residency program. His main areas are laser applications in ophthalmology, diagnosis and treatment of vitreous, retinal and macular diseases, and cataract surgery. Professor Lanzetta is actively involved in retinal clinical research and is currently an investigator in many international multicenter clinical trials on photodynamic therapy, anti-angiogenic and newer drugs and delivery systems.

Assoc. Prof. Gavin Tan

Assoc. Prof. Gavin Tan

Assoc Prof Gavin Tan is Director, Digital Transformation Office & Senior Consultant, Surgical Retina Department, SNEC and Associate Professor, Ophthalmology at Duke-NUS Medical School. He is also the Clinical Director of SNEC Ocular Reading Centre (SORC) that performs centralised grading for the national diabetic screening programme in Singapore – Singapore Integrated Diabetic Retinopathy Programme (SIDRP). He is studying the use of telemedicine, AI and multimodal imaging for diabetic retinopathy. He leads various Clinical Trials at SERI.


Prof. Sehnaz Karadeniz

Dr. Sehnaz Karadeniz is an ophthalmologist and is actively involved in the field of diabetes for the past 25 years. She is the Founding Member and a Member of the Board of Türkiye Diyabet Vakfı (Turkish Diabetes Foundation, TURKDIAB). She is also the President of Diyabetle Yaşam Derneği  (Living with Diabetes Association), a nationwide patients’ organisation, since 2019. Sehnaz joined the board of International Diabetes Federation European Region (IDF Europe) in 2007, and served as the Chair from Dec 2015 to Dec 2019.

Michelle Sylvanowicz

Ms. Michelle Sylvanowicz

Michelle is the Global Advocacy Director, Ophthalmology, at Bayer. Through her collaborative approach, key international organizations like the International Federation on Ageing (IFA), the International Diabetes Federation, and the International Agency for the Prevention of Blindness (IAPB) and the retinal specialist clinical community (Vision Academy (VA) have joined forces with Bayer to run the Diabetic Retinopathy (DR) Barometer Study, and now the sister nAMD Barometer programme.

Note: Owing to regulations and UK compliance, we regret to inform you that we are unable to share Focus on Diabetes content with our UK-based audience.

Supported by:

Programme supported by:

Key partners:

Focus-on-diabetes Key partners: